Annual Drug Patent Expirations for SPRYCEL
Sprycel is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for SPRYCEL.
The generic ingredient in SPRYCEL is dasatinib. One supplier is listed for this compound. Additional details are available on the dasatinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
